CCR4 as a novel molecular target for immunotherapy of cancer.
about
XCL1 enhances regulatory activities of CD4+ CD25(high) CD127(low/-) T cells in human allergic asthmaEngineering humoral immunity as prophylaxis or therapyNew antibody approaches to lymphoma therapyA PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancerCcl22/MDC, is a prostaglandin dependent pyrogen, acting in the anterior hypothalamus to induce hyperthermia via activation of brown adipose tissue.COX-2 and prostaglandin EP3/EP4 signaling regulate the tumor stromal proangiogenic microenvironment via CXCL12-CXCR4 chemokine systems.CCR4 is a determinant of melanoma brain metastasisCADM1 interacts with Tiam1 and promotes invasive phenotype of human T-cell leukemia virus type I-transformed cells and adult T-cell leukemia cellsGenetic Polymorphisms of CCL22 and CCR4 in Patients with Lung Cancer.Down regulation of BCL11B expression inhibits proliferation and induces apoptosis in malignant T cells by BCL11B-935-siRNA.Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis.An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoringCC chemokine receptor 4 modulates Toll-like receptor 9-mediated innate immunity and signaling.Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanomaThe role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spotsControl of the inflammatory response mechanisms mediated by natural and induced regulatory T-cells in HCV-, HTLV-1-, and EBV-associated cancers.LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathwayMicroenvironmental genomic alterations reveal signaling networks for head and neck squamous cell carcinoma.Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression.T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.Effect of cryopreservation on delineation of immune cell subpopulations in tumor specimens as determinated by multiparametric single cell mass cytometry analysis.Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma.Differential correlation analysis of glioblastoma reveals immune ceRNA interactions predictive of patient survivalThe abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis.Immune cell recruitment and cell-based system for cancer therapy.Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome.Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophagesHuman T-lymphotropic virus type 1-induced CC chemokine ligand 22 maintains a high frequency of functional FoxP3+ regulatory T cells.Chemokines shape the immune responses to tuberculosis.Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironmentCCR6 as a possible therapeutic target in psoriasis.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.Calcitonin gene-related peptide biases Langerhans cells toward Th2-type immunityDifferential gene expression profiles of PPP2R5C-siRNA-treated malignant T cells.Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.Chemokine-chemokine receptors in cancer immunotherapy.Ethnoepidemiology of HTLV-1 related diseases: ethnic determinants of HTLV-1 susceptibility and its worldwide dispersal.Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma).Targeting of the innate immunity/inflammation as complementary anti-tumor therapies.
P2860
Q24318773-2AED7146-E558-493E-8FAC-0204200E6650Q26800101-D48093F8-5C3D-4D2A-9473-C1FE81795373Q27022373-5454C761-4A43-44CE-909C-F707B1692B93Q28485246-41A6D1A9-B1CC-4778-BCC2-C60CAC82EC82Q30498100-1B8E4CB9-5562-4EB6-A69C-FB96773AB066Q33703810-9E2DC4F2-E1B5-4BD3-ACB7-11289690A994Q33761639-4B22DCCD-7237-43CE-B9C1-E1AD8F34915AQ33832674-F66DA732-DF9D-4B36-A936-B4FFB57FBE03Q33907317-532BB1C5-5059-4347-9BF9-AA7DB9C060B0Q33960952-8F3C25F7-7142-493E-B8F8-9D863AE44B00Q33982582-6FAE54BF-232B-46FC-ABC1-07E57050D5DEQ33990542-4F43ED60-F01C-4EAB-A7A8-4E3A2E89051EQ34078439-9DD9ACE0-22C6-42A3-9064-EA7ED1DEA4A6Q34111789-CE8E60E7-ACE5-4138-BE2E-6621A04823F1Q34256831-BF294B32-2CC7-4770-B720-38F56B5972A1Q34708248-48D6F142-E945-44D2-946A-52B7FF1DA275Q34952741-8D80FD85-B994-470A-9B24-CC0445C68B60Q35207117-8C8B9D75-BB41-4D44-BD16-4EDFFA8B090BQ35384216-CCF23D62-A542-47A0-A0D5-EB1C3D0F223EQ35632079-E5F4D006-BCE9-4678-ADB4-7E8C90196635Q36266655-5E870F41-EAA3-4C77-BE18-B645F9AB6A2DQ36274579-25CB0DE5-D2BA-447C-B4D0-464A867FA671Q36288217-68A2D7CA-43CF-4A57-8400-1E87882A8C2DQ36292015-EAE16F10-6343-4E67-8130-D57F573FBD73Q36317414-9B5178FF-2C70-48CD-8C67-A9739573772EQ36517706-FC321D5A-069B-4EEF-AB0F-80295A8D0205Q36534138-94A4BA46-2054-49F9-B9A4-0355A6AC0694Q36545368-3C090511-A3D3-4AE4-970F-FB89BD209C33Q36617341-80F4B0D0-82A9-4AB9-8C49-746D280B9600Q36640097-C9DDAEA3-6DC6-44BE-B377-D27865E00390Q36922528-9F824CA9-7256-42B5-A855-6D980E842BF4Q36980670-BE6BC513-D8E4-4A0B-9B3C-653C0F60ECC0Q37055402-85DF07F9-199C-42DB-AB4B-62EA84365418Q37185824-0135F717-E1B0-48EB-A04F-CB1E9119D799Q37202568-CA72B364-6048-42F5-9389-89D1340A00EDQ37276644-6F929FE6-0205-4865-8961-8F214E6076DFQ37773282-231744C7-DDA7-40F2-A1B0-3AA51E30613BQ37825939-58E68A33-20BC-4F4D-B915-D692C51739DFQ37863688-ABE88B4B-E783-47B3-819D-BF5A2476DF5DQ37901025-699947E0-CBDA-47CD-8749-30BA7F2A49DA
P2860
CCR4 as a novel molecular target for immunotherapy of cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
CCR4 as a novel molecular target for immunotherapy of cancer.
@ast
CCR4 as a novel molecular target for immunotherapy of cancer.
@en
type
label
CCR4 as a novel molecular target for immunotherapy of cancer.
@ast
CCR4 as a novel molecular target for immunotherapy of cancer.
@en
prefLabel
CCR4 as a novel molecular target for immunotherapy of cancer.
@ast
CCR4 as a novel molecular target for immunotherapy of cancer.
@en
P2860
P1433
P1476
CCR4 as a novel molecular target for immunotherapy of cancer.
@en
P2093
Ryuzo Ueda
P2860
P304
P356
10.1111/J.1349-7006.2006.00307.X
P577
2006-09-05T00:00:00Z